12:00 AM
 | 
Jun 25, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Livalo: Phase IV data

The double-blind, U.S. Phase IV PREVAIL trial in 328 patients with primary hyperlipidemia or mixed dyslipidemia showed that once-daily 4 mg Livalo led to a median percent reduction in LDL-C, the primary endpoint, of 38.1% from baseline to week 12 vs. 26.4% for once-daily 40 mg pravastatin. Livalo also reduced total cholesterol by 25.8% and APOB by 26.9% vs....

Read the full 273 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >